심혈관 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Cardiovascular Drugs Market is presumed to reach the market size of nearly USD 268.55 Billion by 2032 from USD 183.54 Billion in 2023 with a CAGR of 4.32% under the study period 2024-2032.

Cardiovascular drugs are medications used to treat and manage diseases and conditions related to the heart and blood vessels. These drugs include antihypertensives, statins, anticoagulants, and antiarrhythmics, among others. They are prescribed to manage conditions such as hypertension, coronary artery disease, heart failure, and arrhythmias. These drugs work by various mechanisms, including reducing blood pressure, lowering cholesterol levels, preventing blood clot formation, and stabilizing heart rhythms.

MARKET DYNAMICS

The cardiovascular drugs market is driven by the high prevalence of cardiovascular diseases globally, which necessitates effective pharmaceutical interventions. Advances in drug development and increasing investments in research and innovation contribute to the availability of new and more effective treatments. Opportunities lie in the development of personalized medicine and targeted therapies that offer improved outcomes for patients with specific cardiovascular conditions. Additionally, the growing aging population and rising awareness about heart health drive the demand for cardiovascular drugs. Expanding healthcare infrastructure and increased access to medical care in emerging markets further support market growth. Focusing on preventive care & chronic disease management also creates opportunities for expanding cardiovascular drug offerings. However, stringent regulatory requirements and high R&D costs may restrain the growth of the cardiovascular drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cardiovascular Drugs. The growth and trends of Cardiovascular Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cardiovascular Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers)
• Beta Blockers
• Diuretics
• Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors)
• Antihyperlipidemics
• Other Antihypertensive
• Calcium Channel Blockers
• Others

By Indication

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Peripheral Artery Disease
• Arrhythmia
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cardiovascular Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cardiovascular Drugs market include AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences Inc., Johnson & Johnson, Astellas Pharma Inc., Eli Lilly And Company, Otsuka Holdings Co Ltd., Takeda Pharmaceuticals Company Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CARDIOVASCULAR DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers) Historic and Forecast Sales By Regions
• 5.4. Beta Blockers Historic and Forecast Sales By Regions
• 5.5. Diuretics Historic and Forecast Sales By Regions
• 5.6. Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors) Historic and Forecast Sales By Regions
• 5.7. Antihyperlipidemics Historic and Forecast Sales By Regions
• 5.8. Other Antihypertensive Historic and Forecast Sales By Regions
• 5.9. Calcium Channel Blockers Historic and Forecast Sales By Regions
• 5.10. Others Historic and Forecast Sales By Regions

6. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY INDICATION

• 6.1. Overview By Indication
• 6.2. Historical and Forecast Data Analysis By Indication
• 6.3. Hypertension Historic and Forecast Sales By Regions
• 6.4. Hyperlipidemia Historic and Forecast Sales By Regions
• 6.5. Coronary Artery Disease Historic and Forecast Sales By Regions
• 6.6. Peripheral Artery Disease Historic and Forecast Sales By Regions
• 6.7. Arrhythmia Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 7.5. Online Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CARDIOVASCULAR DRUGS COMPANIES

• 9.1. Cardiovascular Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CARDIOVASCULAR DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. AstraZeneca
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Pfizer Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Novartis AG
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Merck & Co. Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Bristol-Myers Squibb Company
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Bayer AG
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Sanofi
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Boehringer Ingelheim GmbH
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. F. Hoffmann-La Roche Ltd.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Abbott Laboratories
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Gilead Sciences Inc.
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Johnson & Johnson
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Astellas Pharma Inc.
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Eli Lilly And Company
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Otsuka Holdings Co Ltd.
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments
• 10.18. Takeda Pharmaceuticals Company Ltd
  • 10.18.1 Company Overview
  • 10.18.2 Company Revenue
  • 10.18.3 Products
  • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies